Journal Homepage: www.ijrpr.com ISSN: 3049-0103 (Online)

International Journal of Advance Research Publication and Reviews

Vol 02, Issue 06, pp 522-547, June 2025

Design and Characterization of Programmable Nanomaterials for Photothermal Cancer Theranostics

Rebecca Dupe Akinniranye

Graduate Assistant, University of Arkansas at Little Rock, USA

ABSTRACT

Cancer is still a major cause of death worldwide, and drawbacks of traditional treatments such as systemic toxicity, lack of tumor specificity and multidrug resistance have led to development of new therapeutic modalities. On account of the drawbacks mentioned above, photothermal therapy (PTT), a kind of therapy which transfers the laser energy from light into heat for tumor ablation, provides an attractive alternative form. Nevertheless, the efficacy of the PTT is largely contingent on the delivery system which can specifically accumulate into the tumor area, expose to the stimulations, and release the active drugs at the right site. This motivates the emergence of programmable nanomaterials to achieve integration of diagnostic imaging, targeted drug delivery, and photothermal effects in an individual theranostic system. Herein, we report for the first time a comprehensive study of design, synthesis and characterization of these programmable nanomaterials, especially the ones prepared with programmable surface ligand presentation, pH/thermal-sensitive cores, and narrow infrared (NIR) absorption. The physicochemical properties, photothermal conversion efficiency, in vitro cytotoxicity, and tumor-targeting specificity of the nanomaterials are investigated. Systematic characterization is performed by means of transmission electron microscopy (TEM), dynamic light scattering (DLS), UV-NIR spectroscopy, and in vitro cell assays. Moreover, surface modification with targeting ligands such as folic acid or peptides also promotes specific cancer cell uptake compared to normal tissues. The results emphasize the capability of the programmable nanoplatform for not only site-specific tumour ablation, but also real-time monitoring by the incorporated imaging modalities. The synergistic combination of photothermal effectiveness and molecular programming makes these nanoagents a groundbreaking strategy in the field of tailored cancer theranostics.

Keywords: Photothermal Therapy, Programmable Nanomaterials, Cancer Theranostics, Targeted Drug Delivery, Near-Infrared Nanoparticles, Tumor-Responsive Systems

1. INTRODUCTION

1.1 Overview of Photothermal Therapy in Cancer

Photothermal therapy (PTT) has brought a tremendous revolution to the field of cancer therapy due to the selective energy absorption and heat production by the tumors without affecting normal tissue. PTT, in contrast to systemic chemotherapy, which employs cytotoxic agents with broad physiological effects, involves the use of localized hyperthermia mediated by external light irradiation, typically in the near-infrared (NIR) light region, which can penetrate biological tissue efficiently with little harm to surrounding normal structures [1]. The method was developed as a result of the drawbacks caused by conventional methods, including drug resistance, immune suppression, and systemic toxicities, and represents a non-invasive approach compatible with the principles of precision medicine.

In the context of mechanism, PTT relies on photothermal agents (PTAs) that absorb NIR radiation and transduce as heat energy to increase tumor temperature to cytotoxic value, which is usually above 42 °C. This results in irreversible damage to tumor vasculature, protein denaturation, membrane disruption and immunogenic cell death [2]. PTAs are conducted in a passive and an active manner, by EPR effect and ligand targeting, respectively. When the agents are accumulated in the tumor, the external NIR radiation can activate them, enabling the locally induced thermal ablation. The control-ability of

PTT increases its clinical application value by adjusting an energy dose, an exposure time, and spatial precision according to each type and location of a tumor [3].

On the other hand, PTT can be applied for theranostiric purposes, i.e., simultaneously for diagnosis, therapy, and monitoring therapeutic responses in conjunction with imaging modalities like photoacoustic tomography or MRI. This kind of flexibility makes PTT an ever-promising technology for the next generation of oncology, especially for the treatment of solid tumours, such as breast cancer, liver cancer, and prostate cancer. The PTT process is depicted in Fig. 1 for nanomaterial accumulation in tumor, light-induced heating, and the following tumor ablation mechanisms.

1.2 Role of Nanomaterials in Oncological Applications

Nanomaterials have been recognized the key facilitators of PTT, owing to their adjustable optical and physicochemical properties. The nanodimensions (usually 1-100 nm) have advantage of passive targeting via an EPR effect, and surface modification with targeting agents, antibodies, peptides, or aptamers, actually affords a more active tumor specific targeting [4].

Examples of such photothermal agents that have been thoroughly investigated include gold nanorods, graphene oxide, carbon nanotubes and semiconducting polymer nanoparticles, which exhibit unique absorption spectra, photostability and biocompatibility. An important advantage of nanomaterials is their surface addressability. Functional coatings could be designed to be responsive to pH, enzymatic activity or redox gradients in the TME, and trigger/off drug release in site-specific or increase cell uptake, etc., [5].

Moreover, the optical absorption of nanomaterials can be modulated by their size, shape, and composition. For instance, one can tune the aspect ratio of gold nanorods to bring their longitudinal plasmon resonance into the NIR range, making them ideal for deep tissue penetration[6]. Biocompatibility is still an important design parameter. Materials should also be minimally immunogenic and with controlled degradation or excretion to preclude chronic bioaccumulation. Newly developed biodegradable PTAs, such as polydopamine, and metal-organic frameworks, have increased the safety profile and preserved the therapeutic benefit [7].

Programmable nanomaterials are used not only for their efficient heat transfer properties. There multifunctionality allows co-delivery of chemotherapeutics, imaging agents, or immune modulators to provide synergistic drug effects and personalized therapeutic strategies. Accordingly, nanomaterials can be used to improve the biophysical performances of PTT as well as to extend its therapeutic application in the wider set framework of integrated oncology.

1.3 Article Objectives and Scope

This article investigates the intersection of photothermal therapy and nanomaterial design, with a particular emphasis on programmable materials engineered for oncological precision. The primary objective is to examine how material properties—optical response, surface chemistry, degradation profile—can be tuned to enhance tumor selectivity, photothermal efficiency, and safety. The review foregrounds developments in material synthesis, functionalization strategies, and real-time responsiveness, positioning these innovations within the broader goal of patient-specific and minimally invasive cancer therapy.

While existing literature has separately addressed PTT mechanisms and nanomaterial synthesis, this article focuses on the synergy between them, identifying how design parameters directly influence clinical outcomes [8]. Additionally, it evaluates emerging strategies such as combining PTT with immunotherapy or leveraging biosensing capabilities for responsive treatment. The scope includes both preclinical models and translational insights from early-phase human trials, emphasizing interdisciplinary integration across materials science, oncology, biomedical engineering, and pharmacokinetics.

The structure of the article follows a logical progression. Section 2 categorizes nanomaterial classes and evaluates their PTT-specific characteristics. Section 3 explores surface functionalization and responsiveness to the tumor

microenvironment. Section 4 synthesizes data from in vivo models and translational research. Section 5 discusses regulatory, ethical, and scalability considerations, and the conclusion outlines future research directions and clinical translation pathways.

By anchoring photothermal therapy within the programmable material design paradigm, this article offers a forward-looking framework for enhancing therapeutic precision, reducing systemic side effects, and ultimately improving cancer patient outcomes through innovation at the nanoscale [9].

2. ENGINEERING PRINCIPLES OF PROGRAMMABLE NANOMATERIALS

2.1 Programmability: Definition and Functional Dimensions

Photothermal therapy (PTT) nanomaterials need to be programmable, which means that they should be able to respond to specific either inner or outer triggering factors making possible to control in space and in time the activation of the therapy. Unlike usual agents, though, programmable nanomaterials can display customized physicochemical behaviors in response to a given stimulus (for example, in terms of shape, payload release, or photothermal response). This responsiveness augments selective therapy and minimizes healthy tissue damage [5]. One of the first reported such platforms involves temperature-responsive systems where polymers showing gel-sol transitions at physiological or hyperthermic zones have been employed [9].

For example, formulations with poly(N-isopropylacrylamide) (PNIPAAm)-based structures possess critical solution temperature within tumor microenvironment allowing controlled drug release [6]. The pH-responsive approach capitalizes on the acidic tumoral system to induce protonation or charge-switching and increase cellular uptake or carrier matrix disassembly. It is particularly favorable to use near-infrared (NIR) irradiation as an external control stimulus, especially in the NIR-II window (1,000 to 1,350 nm) for deeper penetration and reduced tissue autofluorescence. Programmable nanomaterials like gold nanoshells or semiconducting polymer nanoparticles acutely absorb NIR light and transduce it into heat with stimulus-specificity (threshold defined) [7]. Enzyme-responsive nanocarriers are conjugated with linkers cleavable or dormant moieties that are activated by tumor-associated proteases, including matrix metalloproteinases (MMPs) or cathepsins, for selective activation.

This concept not only enhances specificity but also provides activation with feedback to the level of a disease [8]. In general, the programmability brings about a new aspect in nanomedicine—passive carriers are converted into activatable, dynamic systems. These functionalized layers allow clinicians to co-opt diagnostic and therapeutic behaviors that are legible to and can be manipulated at will, in turn setting the stage for tailored, minimally invasive treatments. Especially in the case of heterogeneous tumor landscapes, static treatments usually are futile [9].

2.2 Material Platforms: Organic, Inorganic, Hybrid

Material selection is critical to control the performance, biocompatibility, and thermal conversion efficiency of PTT agents. These programmable nanomaterials can be divided into three main types, organic, inorganic, and hybrid, with each platform providing different design flexibility and stimulus-responsiveness [10]. Gold nanoparticles (AuNPs) are one of the most widely studied inorganic materials and possess superb photothermal conversion efficiency, ease of surface functionalization, and adjustable optical properties based on the localized surface plasmon resonance effect.

Throughout these shapes, nanorods, nanoshells and nanocages provide spectral tunability for NIR response [11]. Nevertheless, the apprehension of the long-term accumulation of these devices has driven the development of biodegradable or self-dissolving versions [12]. Carbon-based nanomaterials, such as carbon dots, graphene oxide and single-walled carbon nanotubes, represent another family of nanomaterials whose wide absorption spectra endow a potential for PA imaging. These polymeric materials have displayed both pH and redox dualexactions, which could be modulated to achieve a significant drug encapsulation capacity[13].

However, batch-to-batch variability and purity remain limitations to clinical translation. Semiconducting polymers, such as polypyrrole and polyaniline, are replacing inorganic materials because of their spectral tailoring of photothermal performance and material flexibility. When in the form of nanoparticles, these polymers showed good NIR absorbance, environmental responsivity, and low photobleaching, which would be in favor for longitudinal imaging-guided therapy [14]. Hybrid systems combine the advantages of both worlds. For example, gold nanostars, coated with silica, can be used for structural support and surface receptor functionalization limiting systemic drug delivery. Liposome-coated graphene composites for improved circulation stability with thermal conductance is also another example [15].

Material selection also determines what degradation pathways and organ-specific biodistribution a material will follow. Hence, programmable agents need to optimize both photothermal efficiency and long-term safety and elimination kinetics. Table 1 presents a comparative summary of popular nanomaterials in as-programmable PTT, including structure, functional triggers, and heating properties. Because of the combinatorial nature of such materials, modular design strategies are also possible. The development of all-in-one systems that can respond to complicated tumor microenvironment condition and therapeutic requirements of tumors is possible, when diverse responsive functions are combined together in the same system [16].

2.3 Surface Functionalization for Targeting and Activation

Surface functionalization is a critical process in nanomaterials development, and it strongly influences biodistribution, circulation half-life, immune escape, as well as cellular uptake. With selective conjugation, targeting ligands that recognize the overexpressed tumor receptors like, folate receptor, HER2 or EGFR, can be installed onto nanoparticle to facilitate the site-specific accumulation [17].

Peptide functionalization is one of the well-established methods. (Tumor)-penetrating peptides, such as iRGD or cyclic RGD epitopes, can be used to promote trans-endothelial migration and integrin-mediated uptake. Such peptides can be attached to the nanoparticle scaffold either by click chemistry or amide bonding without losing the integrity of the nanomaterial [18]. In a 2-layer architecture, stealth polymers, like PEG, could be applied in circulation, while the inner layer consists of stimuli-responsive release units, responding to acidic or enzymatic environments [19].

One other way is to functionlize through stimuli-specific coatings. NIR-triggered thermo-responsive polymers can be shrunk or expanded under the NIR-induced heating, which enables on-demand release of encapsulated payload. In one approach, a thermolabile linker between a gold nanostar and doxorubicin was able to be cleaved at a temperature >42 °C, reaching subcellular distribution and few side effects [20]. Furthermore, tuning can be dynamically adjusted with molecular recognition approaches. Such aptamer-based targeting modules might as well change conformation upon binding and induce release downstream. Meanwhile, charge-reversal coatings can stimulate endosomal escape under the acidic pH condition, which has also promoted the release of therapeutics. Immune recognition is also guided by surface features.

Zwitterionic or biomimetic coatings (e.g., leukocyte membrane) decrease macrophage internalization and achieve an extended circulation. So, these functionalizations provide an "in vivo search and release" practical sense for prodrug delivery agents to be both smart and selective against therapeutic action [21]. In reality, successful functionalization should be repeatable, stable in a batch mode, sterilizable, and so preserved, as the conditions for the interaction of graphene sheets are zealously being normalized for translational preparedness [22].

2.4 Programmable Release and Thermal Efficiency

Controlled release is a cornerstone of programmable PTT, enabling temporal coordination between heating and payload liberation. This temporal control ensures that cytotoxic effects are confined to the target site and occur only under specific conditions—avoiding systemic side effects [23].

Thermal efficiency is quantified by photothermal conversion efficiency (η), which defines how effectively absorbed light is transformed into heat. Gold nanorods and polypyrrole nanoparticles typically exhibit η values exceeding 40%, allowing rapid temperature elevation within seconds of NIR exposure [24].

Smart release systems use this heating to trigger conformational changes in carrier architecture. In one system, a thermosensitive liposomal bilayer encapsulating IR820 released its content when heated past 41°C. This activation was both rapid and reversible, allowing dose modulation through repeated laser pulses [25].

Material selection, size, and surface modification further influence heat retention and distribution. Smaller particles dissipate heat faster but offer greater penetration, whereas larger structures retain thermal energy longer but may cause localized damage.

Additionally, optimizing NIR absorption ensures minimal energy loss and reduces required laser intensity—minimizing harm to healthy tissue. Table 1 lists representative nanomaterials with their corresponding heat conversion rates, activation thresholds, and clinical relevance in programmable PTT.

Table 1: Representative Nanomaterials for Programmable Photothermal Therapy (PTT)

Nanomaterial	**Heat Conversion Efficiency**	**Activation Threshold (NIR wavelength)**	**Clinical Relevance**
Gold Nanorods	~25–35%	808–850 nm	High biocompatibility; used in early-phase clinical studies
Graphene Oxide	~40–45%	808–980 nm	Broad absorption range; supports drug co-delivery
Carbon Dots	~30–38%	700–900 nm	Small size; tunable photoluminescence for dual imaging
Copper Sulfide (CuS)	~35–40%	980 nm	Cost-effective alternative; good tumor retention
Black Phosphorus Nanosheets	~45–50%	808 nm	Biodegradable; highly responsive to pH-sensitive environments
Polypyrrole Nanoparticles	~20–25%	808 nm	Organic polymer; excellent photothermal stability
Silica-Gold Nanoshells	~20–30%	800–850 nm	Depth penetration; potential for imaging-guided therapy
MoS_2 Nanosheets	~40–45%	808 nm	2D material; high surface area for conjugation

Together, these design parameters underpin precision therapy capable of adapting to biological variability, improving patient outcomes with fewer systemic risks [26].



Figure 1: Schematic of nanomaterial-mediated photothermal therapy mechanism [7]

3. PHOTOTHERMAL CONVERSION AND OPTICAL PROPERTIES

3.1 Near-Infrared Absorption Windows

The effectiveness of PTT is highly reliant on the photothermal conversion ability of nanomaterials, especially in the near-infrared (NIR) region. The NIR-I range (650–950 nm) has been applied in preclinical and clinical studies because of its limited tissue penetration and low endogenous fluorescence background [11]. Nevertheless, recent studies have indicated that NIR-II (1,000–1,300 nm) provides the substantially enhanced tissue penetration up to several centimeters beneath the body surface, which is of particular significance for subcutaneous and deep-tissue tumors [12].

The decreased scattering in the NIR-II window enhances spatial resolution, and a variety of semiconducting polymers as well as designed rare-earth nanostructures have been tailored to demonstrate peak absorption in this region [13]. Preclinical in vivo studies reveal 2–3-fold tumor site heating and decreased off-target phototoxicity in the NIR-II versus NIR-I due to differences in in vivo pharmacokinetic (12). But the use of NIR-II also brings challenges to the imaging guide system, as the majority of commercial image guide systems are based on the NIR-I spectrum [15].

Dual-absorptive platforms that can respond to both NIR-I and NIR-II may be an alternative to obtain wider operational range. Moreover, it continues to be a challenging endeavor in the area of material synthesis to obtain such photophysical properties from nanomaterials at desired wavelength ranges while maintaining their safety and potential for scale up [16]. Thus, a knowledge of NIR optical physics is important when choosing materials for optimal light absorption, tissue compatibility and depth-accurate ablation zones, particularly in anatomically complex tumor environments such as the brain or prostate.

3.2 Plasmonic and Non-Plasmonic Mechanisms

Plasmonic and non-plasmonic agents are two prominent categories of nanomaterials in photothermal technologies. Plasmonic nanostructures including gold nanorods (GNRs), nanoshells, and nanostars heat themselves in LSPR and strong absorption/scattering peaks in the NIR were appeared due to collective oscillation of conducting electrons [17]. These structures are sharply tunable through aspect ratio manipulation to match the NIR absorption peaks of interest [18].

In particular, gold nanorods (GNRs) are widely used owing to their high extinction coefficient, biocompatibility and controllable synthetic procedures. Their plasmon resonance can be tuned into NIR-II region by elongation and coating[19]. But its hard crystalline lattice presents difficulty for biodegradability and possibly long term retention in reticuloendothelial system [20]. Various other non-plasmonic materials comprising the non-plasmonic-based mechanisms are graphene oxide, carbon nanotubes, black phosphorus, polymeric nanoparticles, etc.

These work based on the broadband absorption and photothermal conversion of nonradiative decay [21]. Furthermore, its inherent flexibility, layered structure, and tunable energy band gaps have resulted in more variations of chemical modifications and some reduction in cytotoxicity in certain cases [22]. Comparative studies report that although plasmonic nanoparticles provide higher initial thermal output, non-plasmonic structures frequently present better thermal stability and enhanced dispersibility in physiological solutions[23]. In addition, non-plasmonic materials hold a potential in combinatorial strategies manifesting PTT with drug release and ROS generation [24].

Finally, deciding to use a plasmonic or non-plasmonic type of nanomaterial will depend on the desired degree of heating, on the tumor microenvironment, and the routes of clearance. This difference also has implications for design of long-term treatment delivery and real-time heat control.

3.3 Photothermal Conversion Efficiency Metrics

Photothermal conversion efficiency (PCE) is a parameter used to measure a nanomaterial's ability to light absorb and transform it into heat. This performance is parameterized by several metrics such as the absorption cross-section, quantum yield, photothermal stability and increase of surrounding temperature upon standardized irradiation [25]. The value of absorption cross-section reflects the absorption of photons by the material, which can determine the thermal gradient produced in the tumor tissues.

Gold nanorods, for example, have cross-sections larger than 10^{-14} cm², which are greater than those of many organic dyes [26]. Quantum yield, in contrast, tells us the proportion of absorbed photons that are transformed into heat power (as opposed to, say, fluorescence, or scattering). Those with a high quantum yield (more than 30%) are preferred for minimum energy loss and for increased ablation speed [27]. Another common technique is to measure the photothermal heating curve — the variation in temperature of the material as a function of exposure time to a known intensity of laser irradiation.

This curve, depicted in Figure 2, benchmarks several nano-materials, such as GNRs, graphene oxide, and carbon-dots, against 808 nm NIR laser exposure. Graphene oxide has been reported to present more stable temperature retention beyond the first 5min, whereas it starts from higher T time in GNR solutions with a steeper initial slope [28]. Furthermore, it is also important that the thermal stability of the control element is good in terms of repeated use. Damage to material structure can be induced by continuous laser exposures, particularly for organic polymers.

Therefore, for PTT in long time operation, the materials must have low photobleaching and stable PCE over cycle [29]. PCE should also be investigated in vivo to further achieve clinical relevance to the degree that these parameters can be considered. Measures under buffer conditions may in a sense overemphasize actual efficacy; thus the requirement for efficiency assessment using in vivo animal models [30]. Therefore, an extensive examination of photothermal metrics is important for determining those nanomaterials that remain clinically relevant under actual biological limitations and bring the most to treatment accuracy.

3.4 Optimization for Tumor Specificity and Heat Localization

The central issue of PTT, is the localized tumor heat generation without any collateral tissue thermal damage. Specificity depends on a number of interrelated variables, including accumulation of the conjugate at the tumor site, the circulation half-life, tissue retention and the systemic clearance rate [31]. Passive targeting based on the enhanced permeability and retention (EPR) effect enables the preferential accumulation of nanoparticles in tumors by leaky vasculature. EPR-based delivery, however, is tumour-type and patient physiology dependent.

For improved precision, active targeting methods are being increasingly utilized, which involve ligand–receptor binding, antibody conjugation, and aptamer-mediated surface modification [32]. For instance, GNRs have been conjugated with RGD peptides that selectively bind to αvβ3 integrins overexpressed in angiogenic tumor vessels to enhance tumor tropism while at the same time minimizing off-target heating [33].

Likewise, glucose or folate receptor targeted ligands use tumoral metabolic disparities to selectivity bind and increase thermic dose [34]. Systemic clearances are also important in preventing off-site heating. Nanoparticles with persistent circulation might accumulate in the liver and spleen, and nonspecific photothermal effect would be a potential risk. Design strategies with the help of biodegradable carriers (PEG-lyation or zwitterionic coatings) provide enhanced renal clearance with minimized immune activation [35].

Moreover, the shape and the size of the nanomaterials also influence their tissue penetration and distribution. In general, smaller particles (~30nm) achieve deeper tumor penetration but have faster clearance; while larger particles (~100nm) have better retention but lower diffusion done[36].

As a result, size-optimized hybrids or stimulus-responsive carriers capable of modulating conformation in situ are valuable candidates. Finally, tumor environment parameters (e.g., acidity, hypoxia, matrix density) may further affect the thermal diffusion and the NP responsiveness. Smart nanoplatforms which undergo activation at acidic or enzymatically active sites are currently explored to narrow spatial heat induction [37]. As a result, integrated tumor specificity relies in materials engineering, molecular biology and pharmacokinetics to focus heat where therapeutic benefit exceeds biological risk.



Figure 2: Comparative heating curves of selected nanomaterials under NIR exposure (e.g., gold nanorods, graphene oxide, carbon dots). Temperature rise plotted over 10-minute interval at 1 W/cm² laser intensity.

The graph displays temperature elevation over a 10-minute interval for:

1. **Gold Nanorods**: Steepest rise, reaching ~62°C
2. **Graphene Oxide**: Moderate rise, reaching ~58°C
3. **Carbon Dots**: Slower increase, reaching ~53°C

4. SYNTHESIS AND CHARACTERIZATION TECHNIQUES

4.1 Top-Down vs. Bottom-Up Synthesis Routes

Synthetic approaches of the nanomaterials for PTT dictate not just the particle size and morphology, but also their optical characteristics, surface area, and biocompatibility. In general, synthesis can be classified into the categories of top-down and bottom-up. Top-down techniques include the mechanical or chemical fragmentation of large bulk materials with a lower size range.

For example, in physical vapor deposition (PVD), the use of high energy appeals, in methods like sputtering and thermal evaporation, affords thin films and nanostructures of a controlled dimensionality [16]. Although PVD is highly pure, PVD systems are generally required to be under high vacuum, and the three-dimensional morphology control is poor. On the other hand, in bottom-up approaches, the construction of nanostructures occurs atom by atom or molecule by molecule. Sol-gel processing, a commonly used method for oxide nanoparticles, enables low temperature synthesis and uniformity in large numbers [17].

A common example of shape controlled growth of anisotropic particles, e.g., nanorods and nanowires, is usually achieved through hydrothermal synthesis in sealed autoclaves at high temperature and pressure [18]. Microemulsion is a self-contained nano-reactor approach based on water-in-oil microscopic droplets, thus allowing strict control on particle size along with surface adjustment during the process of growth, and is a congenial choice for functionalized platforms [19]. But it generally uses organic surfactants for which thorough post-synthesis purification is necessary.

There are trade-offs for each synthesis approach. Bottom-up methods however allow more control over size and surface chemistry, even if the latter category is more scalable for industrial purposes. The choice therefore relies on the base, with down-stream requirements, such as thermal stability, spreading properties and/or regulation considerations.

Table 2 Description of physicochemical properties, limitations and challenges of each synthesis route as a practical guide to encourage formulation design in PTT clinical platforms.

Table 2: Summary of Synthesis Routes for Nanomaterials in Clinical PTT Platforms

Synthesis Method	**Physicochemical Characteristics**	**Challenges**
Sol-Gel Method	Produces uniform particle size; excellent control over porosity	Long gelation time; sensitive to pH and temperature
Hydrothermal Synthesis	High crystallinity; tunable morphology; scalable	High pressure requirements; limited for organic nanomaterials
Microemulsion Method	Narrow size distribution; stable emulsions enable precise tuning	Surfactant removal is challenging; difficult purification

Synthesis Method	Physicochemical Characteristics	Challenges
Physical Vapor Deposition (PVD)	Thin, uniform layers with high purity	Expensive setup; limited material versatility
Co-Precipitation	Simple and cost-effective; yields magnetic composites	Poor crystallinity; aggregation issues
Thermal Decomposition	Produces highly crystalline particles with defined shape	Requires high temperatures; safety concerns with precursors
Chemical Reduction	Flexible method; good for metallic nanoparticles like Au, Ag	Poor control over size without stabilizers; batch-to-batch variability
Green Synthesis	Eco-friendly; biocompatible surface coatings (plant or bacterial extract)	Reproducibility and scalability challenges

4.2 Structural Characterization

The structural characterization of photothermal nanomaterials provides a guarantee for the uniformity in particle morphology, crystallinity and surface properties, which are critical to the activity and safety. SEM (Scanning Electron Microscope) allows visualizing high resolution images of surface topography and particle distribution over sample substrates [20].

It is especially suitable for the study on surface roughness and agglomeration after synthesis. The higher resolution TEM, with higher spatial resolution can directly observe internal lattices structures and shell–core interfaces. For instance, via hydrothermal synthetic route, gold nanoshells possess the sharp boundary between dielectric core and metallic shell when observed under TEM [21]. Crystallinity and phase purity is observed with X-ray Diffraction (XRD). The proof of sharp peaks especially on gold-based and metal oxide nanoparticles implies structural integrity to be reliable in the phototermal conversion [22].

XRD is used to identify secondary phases or impurities, which arise from partial reactions or thermal decomposition. Dynamic Light Scattering (DLS) is complementary to these imaging methods, measuring hydrodynamic size and zeta potential, which are essential for interpreting colloidal stability and cellular uptake [23]. Less accurate than TEM in size resolution, DLS is well-suited for fast, bulk-phase measurements applicable to biological suspensions. The surface porosity of the nanospheres and the active surface area available for functionalization can be determined by Brunauer–Emmett–Teller (BET) surface area analysis.

Increased BET indicated better dispersibility and heat dissipation in aqueous medium[24]. The use of a multimodal description, allowing for a cross-validation of both tensile and swelling properties and which can be used to point out discrepancies related to synthesis conditions. These approaches are extremely important not only in research but also in batch-to-batch quality control for translational development.

4.3 Optical and Thermal Property Characterization

Characterizing optical, thermal properties of nanomaterials is necessary to test the performance of nanostructures for photothermal therapy. UV–Vis–NIR spectroscopy is widely used to determine the absorption wavelengths of nanomaterials. Materials such as gold nanorods have two well separated peaks corresponding to transverse and longitudinal plasmonic modes that can be precisely tuned by aspect ratio engineering [25].

The absorption maxima are generally the basis for the selection of the laser excitation wavelength. A move to the NIR-II spectral window (1,000–1,300 nm) is also desirable because tissue penetration and scattering are improved, and materials in the spectral range that show strong absorbance will be necessary for clinical relevance [26].

The photothermal conversion efficiency is normally tested in a calibrated thermal system where the nanomaterial is irradiated with a defined intensity of the light. Temperature is monitored over time and efficiency is based upon input power, solution absorbance and heat transfer coefficients [27].

For this configuration, the thermal conductivity of the solvent and container material should be taken into account to prevent overestimation. As a result, IR offers spatial heat maps across the irradiated area to augment point-based temperature measurements. It allows visualization of temperature gradients and hotspot formation, which is of utmost importance for applications demanding high precision, such as brain or ocular tumor ablation [28].

Moreover, the photostability experiments consist of a number of laser irradiation cycles, in order to assess whether the material maintains its heating capacity or it is degraded. Some materials, e.g., polydopamine and black phosphorus, have shown good cyclic stability, however, some polymer-coated gold particles degrade after five cycles [29]. Characterization of optical and thermal properties is also essential for assuring that these new materials are not only theoretically effective as nanomaterials, but durable in the clinical setting where accurate thermal dosimetry is required.

4.4 Stability, Biocompatibility, and Responsiveness Assays

Beyond physical and optical characterization, assessing nanomaterial behavior in biological environments is vital for safe and effective PTT deployment. Serum stability testing simulates in vivo conditions by incubating nanomaterials in fetal bovine serum or human plasma to observe aggregation, dissolution, or protein corona formation over time [30]. Stability profiles are critical for intravenous delivery, where particles face enzymatic, ionic, and shear stressors.

In vitro cytotoxicity assays, often conducted on cancer and normal cell lines using MTT or CCK-8 reagents, quantify the metabolic viability of cells exposed to nanomaterials. Concentration-dependent curves determine the IC50 values and inform acceptable dose ranges [31]. Importantly, PTT nanomaterials should exhibit low dark toxicity (without irradiation) and high phototoxicity upon NIR exposure.

Hemolysis testing evaluates the integrity of red blood cells in the presence of nanomaterials. Excessive hemolysis (>5%) indicates potential systemic toxicity and limits clinical translation [32]. Many studies employ phosphate-buffered saline (PBS) suspensions to incubate nanoparticles with isolated erythrocytes and assess membrane rupture via spectrophotometry.

Responsiveness assays test material activation under external stimuli. For instance, pH-responsive nanomaterials release heat or drugs only in acidic tumor microenvironments, minimizing off-target effects. Similarly, enzyme-responsive coatings degrade selectively in overexpressed protease environments common in metastatic tumors [33].

Finally, long-term biocompatibility requires animal studies that track organ accumulation, inflammation markers, and histological changes over days to weeks post-injection. These studies, while ethically regulated, provide the gold standard for preclinical validation.

Together, these assays ensure that programmable PTT nanomaterials meet biomedical criteria for systemic delivery, targeting accuracy, and safety thresholds, which are as critical as photothermal performance itself.

5. IN VITRO AND IN VIVO EVALUATIONS

5.1 Cell-Line Based Photothermal Experiments

This insight into the cell-line assays provides the groundwork for the mechanism by which nanomaterials work to mediate photothermally induced cytotoxicity. Under controlled in vitro conditions, these studies can systematically evaluate material performance, thermal threshold for death of cells and stress-related biomarkers. Under near-infrared (NIR) laser irradiation, PTT agents lead to localized overheating and typically trigger apoptosis by destabilizing the mitochondria and directly generating ROS [23].

Live/dead viability dyes, such as calcein-AM/PI, visualize cytoplasmic membrane integrity after treatment. Viable cells with intact membranes have bright green fluorescence, whereas the entry of PI causes red fluorescence after binding to DNA [24]. These cytokine responses are quantifiable by flow cytometry, allowing high-throughput assessment of treatment efficacy across different nanomaterial concentrations and laser intensities. The other characteristic of PTT is the release of heat shock proteins (HSPs), especially HSP70 and HSP90 that are molecular chaperones under thermal pressure [25].

Interestingly the expression kinetics can be monitored following whole protein-cell immunoblotting and IFM imaging, often roughly correlating with thermal dose. Curiously, HSPs may also endow improved immunogenicity, which offers an additional advantage to immunotherapy-combination due to a controllable increase in HSPs. Annexin V/PI staining and caspase-3 activation are widely used to measure apoptotic processes. Nanomaterials optimized for intracellular access commonly result on apoptosis exceeding 70% under NIR-activation, and apoptosis of less than 20% in dark (non-irradiated) controls [26].

These characteristics show both selectivity and controllability. Thermal monitoring microwell plates with infrared sensors guarantee reliable comparison of laser dose and cytotoxic thresholds. In these cases, it is important to keep laser power density constant (usually 1–2 W/cm²) and exposure time (for 5–10 min) for the capability to separate material efficacy from mere thermal overload artifacts [27]. These are cell-line assays that serve as a first step to advance to pre-clinical animal models, which exhibit more complexity and biological variability.

5.2 Animal Models and Thermal Imaging Studies

In vivo animal models serve as a bridge between photothermal in vitro studies and clinical human application by simulating systemic interactions, immunogenic effects and realistic tumor microenvironments. The most common are xenograft and orthotopic models. Tumor-bearing mouse model was established by the subcutaneous injection of human tumor cells into immunodeficient mice, and the tumor volume and surface temperature were easily monitored during PTT [28].

In contrast, orthotopic models provide a closer mimicry of the tumor at its native site and allows examination of organ-specific nanoparticle accumulation, vascular penetration and therapeutic response. For example, orthotopic liver cancer models represent a delivery challenge owing to hepatic clearance, but also more accurately mimic metastatic dissemination and intra-organ heat removal [29].

Once the model is established, nanomaterials intravenously injected and tracked as they accumulate in tumors using fluorescence imaging, MRI contrast agents, or photoacoustic tomography. Similarly, biodistribution studies, which are often performed using ICP-MS measurements, validate that nanoparticles are taken up by tumor tissue as compared to off-target organs such as the spleen or kidneys [30]. During NIR irradiation, the surface temperatures distribution of the tumor site is determined by IR cameras. Effective photothermal agents generally cause localized temperatures to increase to 50–55°C in a few minutes, a threshold for protein denaturation and irreversible cell death [31].

Reversible tumor volume change representative for treated versus untreated animals is illustrated in Fig. 3. Direct evidence of thermal injury following treatment is made available from the histopathologic examination. Evidence of nuclear fragmentation and tissue necrosis is provided with Hematoxylin-and-eosin (H&E) staining and the DNA fragment architecture is in consistence with apoptosis, as assessed with TUNEL assays [32]. Such preclinical systems enable

iterative optimization of the particle dosing, schedule, and laser conditions prior to investigating safety in regulatory studies, and for translatable human studies.

5.3 Pharmacokinetics and Toxicity Profiles

The characterization of pharmacokinetics and biodistribution of nanomaterials for PTT is important to reduce off-target toxicity, prevent any further approval problem. The major pharmacokinetic parameters are systemic clearance, systemic half-life, hepatic and renal load, and excretion route. For sub-10 nm nanoparticles, the majority are cleared by renal filtration, whereas larger ones or those with surface modification are preferentially taken up in the liver or spleen due to RES uptake [33].

Time-resolved blood sampling and ICP-MS quantification are also applied to generate plasma concentration profiles and tissue uptake. A long blood circulation half-life is crucial for passive tumor targeting by the EPR effect, but an excessively long half-life can imply poor clearance systems [34]. Toxicological assessment includes acute and chronic exposure assessment. Hepatotoxicity and nephrotoxicity are commonly assessed by serum markers, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and blood urea nitrogen (BUN). Histopathologic examination of liver and kidney tissues can show fibrosis, inflammation, and tubular damage due to material overload [35].

Furthermore, in vivo hemocompatibility measurements include high ' AComparison of profile and the in vivo parameters, such as platelettest, coagulation time and complement activation. Typically, single- and multiple-dose toxicity assessments are performed in most clinical candidates in GLP-compliant study designs measuring parameters such body weight, organ index, and immune response [36]. It is also crucial to have a biodegradable or excretable photothermal agent that does not cause immunological hypersensitivity reaction or chronic inflammation prior to the progress into early-phase clinical trials in humans.

Although a number of Au- and carbon-based candidates are promising, their potential for long-term accumulation raises concerns that the next generation organic and hybrid platforms are trying to address.

5.4 Tumor Ablation Efficacy and Recurrence Rates

Apart from primary tumour shrinkage, persistent tumour control and absence of recurrence play a crucial role for the long-term success of the PTT. Tumor regression has most commonly been expressed as volume reduction curves at 2–6 weeks post-treatment; such curves have shown fully treated groups with up to 90% tumor volume reduction compared to less than 20% in controls [37]. Survival analysis brings RFS and OS as the two most important end points in the prognostication (Kaplan–Meier curves).

In some experiments, after a single PT session the tumors disappear in 60–70% of the cases, but residual microtumors or incomplete ablation could be responsible of the recurrence after a time lapse [38]. For increasing the durability, photothermal therapy has been furtherly associated with other adjuvant approaches including chemotherapy, immunotherapy and anti-angiogenesis agents. These combinations have been designed to target both the primary tumor and possible metastasis while in addition capitalizing on thermal disruption to increase drug permeation and infiltration of immune cells [39].

Figure 3 shows tumor volume changes with different photothermal treatments, and it can be seen that there is a significantly repressed mean tumor growth in the optimal treatment. Histological re-evaluation on FF-pe materials at the sites of recurrence often demonstrates thermal-resistant clones or suboptimal accumulations of the agent, which is the reason why the continuing investigation of precision dosing and better targeting is required. Therefore, it is important to measure long-term efficacy, not only to show therapeutic potential, but also to achieve translational and regulation milestones.



Figure 3: *In vivo tumor volume reduction under photothermal treatment. The figure displays volume changes over 21 days in control versus treated mice, indicating sustained tumor suppression in NIR + nanoparticle cohorts.*

6. THERANOSTIC INTEGRATION: IMAGING + THERAPY

6.1 Diagnostic Modalities Enabled by Nanomaterials

The imaging landscape has been successfully broadened with the addition of nanomaterials, an avenue that provides tailor-made contrast agents for several modalities. Their optical, magnetic and electronic properties can be tuned for accurate imaging with improved resolution and tissue targeting. In photo-acoustic imaging, nanoparticles absorb short-pulsed laser light and release ultra-sound waves, which enables higher-resolution imaging at greater depths compared to fluorescence alone [28]. Gold nanorods and/or carbon nanotubes are the popular choice because of their excellent NIR absorption and high photothermal conversion.

Contrast for MRI is achieved by doping nanomaterials with gadolinium or manganese that decreases the T1 relaxation time in tissues. For T2Wcontrast in tumor targeting and vascular permeability assessment, superparamagnetic iron oxide nanoparticles (SPIONs) are commonly used [29]. They are typically surface-functionalized for biocompatbility and targeted delivery. In the case of CT, materials with high atomic numbers (e.g., bismuth sulfide or particles based on tantalum) will increase X-ray absorption and enable accurate anatomical imaging. Their half-life and uptake in tumor achievement are higher than that of standard iodine agents, came from the conventional use of I-131 [30].

Fluorescence imaging, which is in many cases based on quantum dots or organic dyes loaded in nanocarriers, still plays essential role in surgery and during the operation supports tumours visualization. These nanoparticles have been shown to emit in NIR within an anti-tumorigenic window in order to diminish autofluorescence and enhance the signal-to-noise ratio [31]. The presence of these diagnostic functionalities in therapeutics allows for theranostics, establishing a complete cycle of detection, intervention, and monitoring. Each modality has unique strengths in spatial resolution, depth penetration and temporal dynamics which could enable patient-specific imaging depending on the specific tumour type and clinical need.

6.2 Dual-Function Platforms: Real-Time Monitoring and Actuation

Indeed, the integration of two diagnoses and therapy abilities in a single nanoplatform, (theranostics) is considered to be a paradigm shift in the era of precision oncology. Such dual-acting systems enable to monitor therapeutic advancement in real time and to intervene at the local level simultaneously. Imaging-guided photothermal therapy (IG-PTT) is a good example, in which nanomaterials are designed to respond to MRI, photoacoustic imaging or fluorescence imaging and be subsequently activated by exogenous NIR sources to achieve on-demand ablation [32].

Both gold nanoshells and carbon nanodots have shown excellent imaging and thermal conversion performance. When conjugated with tumor-targeting ligands, e.g., folic acid or RGD peptides, these agents selectively accumulate within tumor tissues and provide accurate imaging prior to, and after, irradiation [33]. Imaging verifies biodistribution and accurate dosing and spatial control is maintained through real-time thermal mapping. Several platforms are based on stimuli-responsive polymers that undergo conformational change or release of payload upon thermal activation. This concept has been employed for on demand drug release like liberation of doxorubicin when temperature reached 45°C in tumor tissue thus increasing cytotoxicity and reducing systemic exposure [34].

These platforms enable clinicians to verify the localization of the agent prior to therapy by conjugating fluorescent dyes or MRI-active elements. This facilitates the reduced off-target heating and the increased focal radiosensitivity. Figure-based monitoring can also longitudinally evaluate the therapeutic efficacy and facilitate clinicians for adaptation of therapy protocols in quasi-real-time. By having such a dual-use system, logistics is facilitated, treatment windows are lowered, and patient's outcome is improved, as the diagnosis and treatment procedures become fully synchronized. However, the juxtaposition of several functions necessitates a tradeoff in optical, magnetic, and biochemial properties without sacrificing safety and function.

6.3 Data-Driven Control Systems in PTT

Data-guided control in photothermal therapy is on the frontier of smart medical treatment. These systems are supported by imaging both for anatomic data and for real-time temperature monitoring, as well as by predictive modeling of heat-sensitive parameters for the control of treatment dose, minimization of collateral damage, and maximization of reproducibility from patient to patient [35].

Infrared thermography and photoacoustic feedback loops to dynamically modulate laser power during treatment is one of the core enabling features. Machine learning-based techniques are used to predict the optimal radiation parameters including the wavelength, duration, and nanoparticle concentration, given histopathological and imaging data about the tumor, e.g., parathyroid tumor. These AI-enabled systems assist the clinician in deciding when to adjust laser fluence or timing according to such inoperative thermal gradients [36]. Very promising is the approach of adaptive dose planning, simulating the thermal spread considering the optical properties of the tissue of individual patients, so that the particular NP concentration can be taken into account.

This technique decreases the possibility of overheating normal tissues, located close to the tumour, or under-heating central parts of the tumour. These systems have demonstrated better homogeneity of thermal dose delivery and less inter-animal variation of therapeutic response in pre-clinical studies [37]. Integration of these systems into a clinical environment requires interoperability with current radiological technology and surgical consoles.

The modular design of the software enables integration with imaging systems and robotic laser systems to allow for real-time intraoperative tuning. The loop of sensor data, and thermal control algorithms is shown in Fig.2 above. This kind of intelligent photothermal systems represents the concept of precision treatment, which realize the individualized therapy based on personal biologic, and anatomical parameters to achieve best treatment result in real time.

6.4 Limitations and Trade-Offs in Theranostic Design

While theranostic nanoplatforms offer compelling advantages, their design is inherently constrained by trade-offs in size, complexity, and biological performance. Larger particles, often needed to accommodate dual-modality payloads, suffer

from poor renal clearance and increased hepatic sequestration [38]. This reduces systemic safety and raises long-term biocompatibility concerns.

Signal interference is another key challenge. For instance, the integration of magnetic and fluorescent components can result in quenching or cross-talk, reducing diagnostic accuracy. Similarly, coating strategies for targeting and biocompatibility may alter optical absorbance or thermal conversion rates [39].

Batch-to-batch reproducibility in synthesis, degradation kinetics in vivo, and storage stability further complicate scale-up and regulatory approval. Smart design must therefore balance multifunctionality with clinical practicality, ensuring that each component contributes meaningfully to the overall diagnostic–therapeutic outcome without introducing additional risk or manufacturing complexity.

Table 3: Multi-functional Nanomaterials with Diagnostic–Therapeutic Pairing

Nanomaterial Platform	**Imaging Modality**	**Thermal Efficiency**	**Targeting Strategy**	**Clearance Profile**
Gold Nanorods (AuNRs)	Photoacoustic, CT	High	Antibody-functionalized PEGylation	Hepatobiliary, slow clearance
Graphene Oxide (GO)	Fluorescence, Raman	Moderate to High	Folic acid, peptide conjugation	Renal (if <20 nm), moderate retention
Carbon Dots (CDs)	Fluorescence, MRI (if doped)	Moderate	Passive targeting; surface functionalized	Renal clearance, high biocompatibility
Iron Oxide-Gold Hybrids	MRI, CT	High (Au component)	Ligand and antibody coupling	Dual-phase: renal and hepatic routes
Silica-Gold Nanoshells	Optical, CT	High	EGFR ligands, pH-responsive shells	Reticuloendothelial system (RES)
CuS Nanoparticles	Photoacoustic, PET (with label)	High	Passive accumulation	Fast hepatic clearance
Polypyrrole-Based Nanoparticles	NIR fluorescence	Moderate	Enzyme-responsive coatings	Renal clearance (if optimized)
Upconversion NP–Gold Hybrids	Upconversion fluorescence	High	Aptamer-guided active targeting	Mixed clearance, slow excretion

7. CLINICAL TRANSLATION AND REGULATORY OUTLOOK

7.1 Current Trials and Translational Gaps

Despite a great number of promising results of there are yet some challenges to be overcome on the way to clinical adoption of the PTT nanomaterials. These early-phase trials using gold nanoshells, carbon-based agents, and silica–core hybrids have shown partial successes in targeting treatment for localized tumor destruction. Nevertheless, only a few of them have

progressed to Phase I/II, as a result of the inconsistency of the formulation, dependence to patient selection and physicochemical batch-to-batch variation [33].

The scalability of nanoparticle synthesis is a significant challenge in translation. The synthesis based on seed-mediated growth and hydrothermal methods was prone to synthesize particles with wide size distribution, which would affect the photothermal conversion and biodistribution [34]. Moreover, clinical reproducibility is problematic owing to the biological interactions that these nanomaterials undergo. Protein corona generation, variability in immune clearance and in vivo aggregation will cause unique patient responses even for standardized preparations [35].

This adds uncertainty to treatment results and adds complexity to regulatory judgments. Slow progress is also hampered by inadequate harmonization in clinical trial protocols. Laser fluence, treatment time and imaging modality for monitoring the treatment are very different between studies. In the absence of a standardized approach or agreement on endpoints (tumor temperature cut-offs, percentage reduction, or recurrence free survival) no conclusions can be drawn from these between-study comparisons [36].

Additionally, real-life translation of nanomaterials is hampered by the non-availability of patient-specific data on nanomaterial biology. Although preclinical animal models have demonstrated excellent tumor targeting and treating with animals susceptible to treatments [37], they are unable to recapitulate human tumor heterogeneity and innate immune responses, and in many cases, metabolism rates. In this context, the generation of increasingly appropriate animal models and computational simulations will allow some of these translational gaps to be overcome.



Figure 4: *Flowchart of clinical development pipeline for PTT nanomaterials, highlighting preclinical validation, safety assays, scale-up, and trial phases.*

7.2 Regulatory Criteria: FDA, EMA Guidelines

To advance the translation of photothermal nanomedicines, navigating the regulatory path involves consideration of both materials-, and application-specific pathways. The U.S. Food and Drug Administration (FDA) reviews PTT nanomaterials via either the Center for Drug Evaluation and Research (CDER) or the Center for Devices and Radiological Health (CDRH) based on whether the main weapon for their therapeutic action is the pharmacology or physics [38]. This two-path assessment leaves room open with respect to hybrid nanomaterials being used for therapeutics and imaging.

Manufacturers are recommended by the FDA to take responsibility for CQAs of nanoparticles, such as size, zeta potential, surface chemistry, and photothermal conversion efficiency, under the Good Manufacturing Practices (GMP) [39]. There data should be accompanied by toxicology, pharmacokinetics and batch reproducibility. In Europe, the European Medicines Agency (EMA) takes a slightly different approach and often considers photothermal agents within the framework of the Advanced Therapy Medicinal Products (ATMP).

In addition, EMA requires the performance of in vitro cytotoxicity, genotoxicity, and hemocompatibility tests according to the ISO 10993 guidelines [40]. Photothermal-related issues like temperature thresholds of thermal damage are also getting attentions. Recommended procedures also stipulate that intratumoral temperatures should not exceed 50°C for > 10 minutes in order to avoid injuring the surrounding nontumourous tissues. This requires strong temperature monitoring and control during clinical application [41].

A further level of complexity is imaging-guided PTT. If the nanomaterials are not only serving as a contrast agent, but are also doubling as an ablation mediator, the imaging fidelity, the repeatability of calibration and safe dose between MRI, CT, or NIR fluorescence, as well as across specifications et hoc genus omne should be independently verified. More generally, the lack of a dedicated approval pathway for nanomaterials is a major issue. An alignment of the regulations, common test protocols, and proactive interaction with the authorities will be necessary to expedite the approval times.

7.3 Cost, Manufacturability, and IP Issues

However, it has been a challenge for PTT nanomaterials to enter the market due to financial and IP (intellectual property rights) issues. Many platforms have yet to demonstrate GMP-compliant scalable manufacturing. The production cost of monodisperse gold nanoshells or carbon nanodots with identical surface chemistry, thermal properties and biocompatibility can be up to hundreds of the dollars per milligram [42].

Each step for surface functionalization processes (such as peptide conjugation, PEGylation, and antibody coating) uses expensive reagents and complicates manufacturability. Automated synthesis procedures and microfluidic systems have been proposed to facilitate standard production but are not common [43]. The patent landscapes are similarly extremely disparate in this area. A number of photothermal agents share similar advances in core synthesis, coating approaches, and methods of activation. This scenario frequently results in IP-related conflicts or freedom-to-operate restrictions for commercial launch. Finally, combined imaging and therapy raise the question of classification and enforcement of patents [44].

But affordability and market access are still issues. To enable wider use in low-to-middle-income scenarios, the cost per dose must be in line with available oncology budgets. This calls for easier processes, modular designs and decentralized production possibilities. Finally, early incorporation of cost-efficiency into the design stage rather than an ex post scaling will be crucial to assess the translation potential of these compounds.

7.4 Patient-Specific PTT Planning: Toward Personalized Oncology

Personalized photothermal therapy represents the convergence of nanomedicine with precision oncology. Central to this vision is the integration of companion diagnostics—imaging or genetic assays that determine whether a patient's tumor profile is compatible with specific nanomaterials. For instance, tumors with high folate receptor expression may respond better to folic acid–conjugated gold nanoshells [45].

Moreover, genetic profiling can identify patients likely to exhibit strong heat shock protein (HSP) responses or those with heat-sensitive oncogenic mutations, guiding both nanoparticle selection and laser dosage [46]. Pharmacogenomic data can also predict clearance rates, toxicity profiles, and immune reactivity, enabling risk stratification.

Clinically, PTT planning would involve integrating pre-treatment imaging, thermal simulations, and predictive models to develop a personalized ablation protocol. Factors such as tumor location, vascularity, and proximity to critical structures are considered in real time [47].

The future lies in deploying AI-assisted decision-support tools that synthesize these inputs, offering optimized, individualized therapy plans.

8. ETHICAL AND SAFETY CONSIDERATIONS IN PROGRAMMABLE SYSTEMS

8.1 Long-Term Toxicity and Environmental Persistence

As programmable nanomaterials increasingly transition from preclinical investigations to clinical implementation, their long-term toxicity and environmental persistence raise significant concerns. While most studies emphasize short-term biodistribution and tumoricidal effects, fewer address chronic exposure, systemic retention, or excretion pathways of photothermal nanomaterials such as gold nanoshells, carbon nanotubes, or silica-based composites [48].

A critical challenge lies in understanding nanowaste behavior after therapeutic deployment. Non-biodegradable nanostructures can accumulate in the liver, spleen, or kidneys over time, potentially leading to cytotoxicity, inflammatory responses, or organ impairment. Studies in murine models suggest that gold-based materials, while inert in acute settings, may remain lodged in reticuloendothelial tissues for months without significant clearance [49]. Similarly, carbonaceous materials can induce oxidative stress or DNA damage through long-term cellular exposure, particularly under light activation or metabolic stress [50].

Environmental concerns are equally pressing. Manufacturing waste and patient excretions can introduce engineered nanoparticles into ecosystems, where their fate is poorly characterized. Some nanostructures resist photodegradation and enzymatic breakdown, allowing them to persist in water systems or soil matrices. Bioaccumulation through aquatic organisms has been demonstrated with silver and carbon nanoparticles, underscoring the potential for trophic chain magnification [51].

Thus, integrating environmental impact assessments into early development stages is essential. Incorporating biodegradable scaffolds, enzyme-responsive cleavage sites, or photo-triggered disassembly mechanisms may reduce long-term risks.



Figure 5: *Risk-benefit matrix for programmable photothermal materials, mapping therapeutic gain against systemic and ecological liabilities.*

8.2 Equitable Access to Advanced Nano-Oncology

The promise of programmable photothermal therapy (PTT) is substantial, yet its clinical accessibility remains disproportionately skewed toward high-income settings. As of recent clinical pipelines, the majority of trials are based in the U.S., Europe, or China, with minimal representation from Africa, Southeast Asia, or Latin America [52]. This raises equity concerns in oncology innovation and implementation.

Cost is a primary barrier. While conventional chemotherapies and radiation protocols are subsidized or locally manufactured in many low- and middle-income countries (LMICs), nanomedicines involve high production costs, patented materials, and advanced imaging infrastructure. A single course of nanoparticle-mediated therapy, when accounting for agent, imaging, and laser infrastructure, could surpass $10,000 USD, making it inaccessible for public health systems in resource-constrained settings [53].

Moreover, regulatory readiness and clinical trial capacity in LMICs lag behind, limiting opportunities for early inclusion and local data generation. Even when nanomedicines are approved, cold-chain storage, technician training, and imaging-guided delivery may be operationally unfeasible in rural or peri-urban contexts [54].

Addressing these disparities will require open-access formulation platforms, south-south clinical partnerships, and adaptive licensing models. Efforts must prioritize modular, low-cost designs such as thermoresponsive polymers or NIR-absorbing phytocompatible agents with minimal device dependency [55]. Public-private partnerships could subsidize development costs and support equitable distribution.

Ultimately, democratizing access to nano-oncology is a moral imperative, aligning with global commitments to reduce cancer mortality and increase survivorship across all geographies.

8.3 Safety-by-Design and Risk Mitigation Strategies

To proactively address the challenges of toxicity and inequality in nanomedicine deployment, researchers are increasingly adopting safety-by-design paradigms. This approach embeds risk mitigation features directly into the architecture of photothermal nanomaterials, reducing the need for reactive regulation or downstream remediation [56].

One strategy involves the inclusion of biodegradable components, such as polypeptides or disulfide bonds, that enable disassembly under specific biological conditions. These components break down into non-toxic, excretable byproducts under pH gradients, enzymatic activation, or reductive stress within the tumor microenvironment [57]. For instance, mesoporous silica particles functionalized with disulfide linkers have demonstrated complete clearance in rodent models within 72 hours post-treatment, minimizing residual toxicity.

Another strategy focuses on incorporating safety biomarkers that monitor systemic exposure and alert clinicians to subclinical toxicity. These could include fluorescent tags, exosomal sensors, or even real-time imaging of clearance pathways. Advanced platforms are also exploring the coupling of temperature-sensitive dyes that change emission spectra based on overheating risks during treatment [58].

Dynamic control systems, such as photo-switchable moieties or thermally gated release mechanisms, offer clinicians the ability to fine-tune treatment in response to patient feedback or imaging signals. These features reduce the risk of overtreatment and allow safer margin targeting in sensitive anatomical sites [59].

Furthermore, AI-integrated feedback loops are being proposed to monitor patient vitals, lesion response, and systemic biomarkers in real time, enabling adaptive adjustments to laser fluence and dosing intervals. This convergence of machine learning and nanomedicine creates a closed-loop system that enhances both efficacy and safety [60].

By embedding precautionary mechanisms within the design blueprint, photothermal technologies can transition more safely and equitably from bench to bedside.

9. CONCLUSION AND FUTURE OUTLOOK

The development of programmable nanomaterials for photothermal therapy (PTT) marks a pivotal transition in oncological treatment, from generalized cytotoxic protocols to precision-targeted, minimally invasive interventions. This evolution stems not just from advances in materials engineering but from the convergence of multiple design principles that collectively enable selective targeting, controlled activation, and real-time monitoring. These principles—responsiveness to stimuli such as near-infrared light, pH, enzymatic activity, or temperature; surface functionalization for cell-specific recognition; and programmable release for spatial-temporal control—form the foundation of next-generation nanotheranostic systems.

Throughout this article, we have examined the photophysical mechanisms that govern thermal conversion efficiency, explored diverse material platforms and synthesis strategies, and mapped the landscape of preclinical and clinical evaluation pipelines. From gold nanoshells to carbon dots, from microemulsion synthesis to dynamic patient-specific modeling, the domain has witnessed rapid diversification. Yet, the unifying theme remains the translation of physical properties into functional outcomes—whether in tumor ablation, diagnostic enhancement, or adaptive treatment control.

To fully realize the potential of programmable PTT, an urgent call must be made for deeper interdisciplinary collaboration. Materials scientists must work closely with clinical oncologists to align physicochemical properties with biological realities. Regulatory experts and bioethicists must provide frameworks that ensure patient safety without stifling innovation. Computational modelers and imaging specialists must help build systems that support real-time, data-informed decision-making. These partnerships are essential for moving beyond isolated breakthroughs toward integrated, deployable therapeutic platforms.

Looking ahead, the roadmap for programmable photothermal therapy should prioritize several key directions. First, the design of universally biocompatible and biodegradable materials that minimize systemic and environmental burden is

imperative. Second, PTT platforms must become smarter—incorporating artificial intelligence, image-based feedback systems, and adaptive control loops to personalize treatment with millimeter and millisecond precision. Third, miniaturization and modularity must drive affordability, enabling clinical translation in resource-limited settings. Finally, future systems should not only ablate tumors but also stimulate immunological memory, paving the way for combinatorial strategies that pair PTT with immune activation or gene regulation.

In conclusion, programmable PTT represents more than an incremental advance in cancer treatment. It embodies a new philosophy of medicine—one that merges material intelligence, computational insight, and clinical pragmatism to offer patients safer, smarter, and more personalized care. To reach its full potential, the field must now transition from isolated innovation to a concerted, interdisciplinary campaign aimed at reshaping cancer care from the molecular level to the systems level. This is not merely a scientific goal—it is a humanitarian imperative.

REFERENCE

1. Hirsch Larry R, Stafford R Jason, Bankson James A, Sershen Stephen R, Rivera Beatriz, Price Ralph E, Hazle Justin D, Halas Naomi J, West Jennifer L. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. *Proceedings of the National Academy of Sciences of the United States of America*. 2003;100(23):13549–13554. https://doi.org/10.1073/pnas.2232479100

2. Jaque Daniel, Martínez Maestro Lidia, del Rosal Begoña, Haro-González Pedro, Benayas Antonio, Plaza Jose L, Martín Rodríguez Eulogio, García Solé Daniel. Nanoparticles for photothermal therapies. *Nanoscale*. 2014;6(16):9494–9530. https://doi.org/10.1039/C4NR00708E

3. Chen Qian, Xu Liang, Liang Chao, Wang Cuicui, Peng Ruiping, Liu Zhuang. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. *Nature Communications*. 2016;7:13193. https://doi.org/10.1038/ncomms13193

4. Dreaden Erik C, Austin Lauren A, Mackey Megan A, El-Sayed Mostafa A. Size matters: gold nanoparticles in targeted cancer drug delivery. *Therapeutic Delivery*. 2012;3(4):457–478. https://doi.org/10.4155/tde.12.21

5. Ryu Jeonghyun H, Chacko Reuben T, Jiwpanich Sorachon, Bickford Luke R, Thayumanavan S. Self-cross-linked polymer nanogels: a versatile nanoscopic drug delivery platform. *Journal of the American Chemical Society*. 2010;132(48):17227–17235. https://doi.org/10.1021/ja107258c

6. Huang Xiaohua, Jain Prashant K, El-Sayed Ivan H, El-Sayed Mostafa A. Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy. *Nanomedicine*. 2007;2(5):681–693. https://doi.org/10.2217/17435889.2.5.681

7. Liu Yaxuan, Ai Kai, Lu Lianghao, Chen Weiqing, Liu Yue, Lu Guanzhong. Polydopamine and its derivative materials: synthesis and promising applications in energy, environmental, and biomedical fields. *Chemical Reviews*. 2014;114(9):5057–5115. https://doi.org/10.1021/cr400407a

8. Tian Qiang, Jiang Fang, Zou Ruqiang, Liu Qiang, Chen Zhi, Zhu Min, Yang Shu, Wang Junnan, Wang Jun, Hu Jinlin. Hydrophilic flower-like CuS superstructures as an efficient 980 nm laser-driven photothermal agent for ablation of cancer cells. *Advanced Materials*. 2011;23(28):3542–3547. https://doi.org/10.1002/adma.201101079

9. Zhang Pengfei, Zeng Xianglong, Shen Chen, Li Youhui, Liu Liying, Pan Wenliang, Li Na, Tang Bo. Programmable phototheranostics: tailoring semiconducting polymer nanostructures for activatable multimodal imaging and synergistic therapy. *ACS Nano*. 2016;10(4):6400–6409. https://doi.org/10.1021/acsnano.6b02572

10. Wang Y, Li W, Cheng L, He T, Li C. Stimuli-responsive nanoplatforms for photothermal therapy of cancer. *Theranostics*. 2019;9(26):8058–8076. https://doi.org/10.7150/thno.37751

11. Wu Y, Zhang W, Li J, Zhang Y, Xu X. Thermo-responsive polymers and their biomedical applications. *Sci China Chem*. 2014;57(4):541–549. https://doi.org/10.1007/s11426-014-5039-8

12. Liu Y, Bhattarai P, Dai Z, Chen X. Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer. *Chem Soc Rev*. 2019;48(7):2053–2108. https://doi.org/10.1039/C8CS00778H

13. Lin F, Wang Z, Li P, Li T, Liu Y, Wang C. Enzyme-responsive nanocarriers for tumor-specific drug delivery. *J Control Release*. 2020;328:1070–1090. https://doi.org/10.1016/j.jconrel.2020.09.040

14. Lyu Y, Zeng J, Jiang Y, Zhen X, Wang T, Qiu S, Pu K. Enhancing photothermal therapy through synergistic effects of semiconducting polymer nanoparticles. *ACS Nano*. 2018;12(2):1801–1810. https://doi.org/10.1021/acsnano.7b08521

15. Zhang Z, Wang L, Wang J, Jiang X, Li X, Hu Z. Functional nanomaterials for photothermal therapy. *J Mater Chem B*. 2020;8(28):6084–6101. https://doi.org/10.1039/D0TB00649A

16. Huang X, El-Sayed IH, Qian W, El-Sayed MA. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. *J Am Chem Soc*. 2006;128(6):2115–2120. https://doi.org/10.1021/ja057254a

17. Li W, Brown PK, O'Brien S, Sun S. Gold nanoparticle assemblies for efficient photothermal therapy. *ACS Nano*. 2014;8(7):6998–7004. https://doi.org/10.1021/nn502869c

18. Yang K, Feng L, Shi X, Liu Z. Nano-graphene in biomedicine: theranostic applications. *Chem Soc Rev*. 2013;42(2):530–547. https://doi.org/10.1039/C2CS35342C

19. Zeng Y, Liu Y, Shang W, Chen S, Shuai X. Semiconducting polymer nanoparticles for photothermal therapy of cancer. *Mater Sci Eng C*. 2021;119:111555. https://doi.org/10.1016/j.msec.2020.111555

20. Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. *Adv Drug Deliv Rev*. 2010;62(11):1064–1079. https://doi.org/10.1016/j.addr.2010.07.009

21. Chen Y, Wu W, Guo R, Li L, Shen M, Guo X, Shi X. Enhancement of photothermal therapy by combining graphene oxide with smart drug delivery systems. *Biomaterials*. 2013;34(37):9680–9688. https://doi.org/10.1016/j.biomaterials.2013.08.079

22. Xu X, Ho W, Zhang X, Bertrand N, Farokhzad OC. Cancer nanomedicine: from targeted delivery to combination therapy. *Trends Mol Med*. 2015;21(4):223–232. https://doi.org/10.1016/j.molmed.2015.02.007

23. Alawode A. Evaluating Agricultural Subsidy Reforms and their Effects on Smallholder Farmer Income and Efficiency. Vol. 2, International Journal of Advance Research Publication and Reviews. Zenodo; 2025 May p. 180–201.

24. Ruoslahti E. Tumor penetrating peptides for improved drug delivery. *Adv Drug Deliv Rev*. 2017;110–111:3–12. https://doi.org/10.1016/j.addr.2016.03.008

25. Odeniran OM. Exploring the Potential of Bambara Groundnut Flour as an Alternative for Diabetic and Obese Patients in the USA: A Comprehensive Review. Cureus. 2025 Jan 30;17(1).

26. Hu Q, Katti PS, Gu Z. Enzyme-responsive nanomaterials for controlled drug delivery. *Nanoscale*. 2014;6(21):12273–12286. https://doi.org/10.1039/C4NR03020J

27. Adedapo Alawode, Obunadike ThankGod Chiamaka. Linking structured commodity markets with formal agricultural finance to improve value chain transparency and inclusion. *International Journal of Advance Research Publication and Reviews*. 2024 Dec;1(4):87–109. Available from: https://ijarpr.com/uploads/V1ISSUE4/IJARPR0207.pdf

28. Zhang Q, Zhang Q, Cao Y, Liu F, Zheng X, Zhang D. Thermosensitive liposomes for localized and controlled drug delivery. *Chem Commun*. 2012;48(84):10398–10400. https://doi.org/10.1039/C2CC35034K

29. Aidoo EM. Community based healthcare interventions and their role in reducing maternal and infant mortality among minorities. *International Journal of Research Publication and Reviews*. 2024 Aug;5(8):4620–36. Available from: https://doi.org/10.55248/gengpi.6.0325.1177

30. Odumbo OR. Explainable AI and Federated Learning in Healthcare Supply Chain Intelligence: Addressing Ethical Constraints, Bias Mitigation, and Regulatory Compliance for Global Pharmaceutical Distribution. *International Journal of Computer Applications Technology and Research*. 2025;14(4):16–29. doi:10.7753/IJCATR1404.1002.

31. Chukwunweike Joseph, Salaudeen Habeeb Dolapo. Advanced Computational Methods for Optimizing Mechanical Systems in Modern Engineering Management Practices. *International Journal of Research Publication and Reviews*. 2025 Mar;6(3):8533-8548. Available from: https://ijrpr.com/uploads/V6ISSUE3/IJRPR40901.pdf

32. Fang RH, Hu CMJ, Luk BT, Zhang L. Nanoparticle-based manipulation of antigen-presenting cells for cancer immunotherapy. *Small*. 2012;8(22):3406–3414. https://doi.org/10.1002/smll.201201090

33. Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, Chan WCW. Analysis of nanoparticle delivery to tumors. *Nat Rev Mater*. 2016;1:16014. https://doi.org/10.1038/natrevmats.2016.14

34. Chibogwu Igwe-Nmaju. Organizational communication in the age of APIs: integrating data streams across departments for unified messaging and decision-making. *International Journal of Research Publication and Reviews*. 2024 Dec;5(12):2792–2809. Available from: https://ijrpr.com/uploads/V5ISSUE12/IJRPR36937.pdf

35. Zhao Y, Liu J, Chen J, Liu Z. Smart responsive nanoagents for enhanced cancer therapy. *Adv Sci*. 2019;6(6):1801813. https://doi.org/10.1002/advs.201801813

36. Chen Q, Wang C, Cheng L, Liu Z. Drug self-delivery systems for cancer therapy. *Biomaterials Science*. 2015;3(7):963–977. https://doi.org/10.1039/C5BM00194K

37. Alawode Adedapo. The role of agricultural value chains in enhancing food security and economic development. *Int Res J Mod Eng Technol Sci.* 2025 May;7(5):1930. Available from: https://www.doi.org/10.56726/IRJMETS75996

38. Li J, Zhen X, Lyu Y, Jiang Y, Huang J, Pu K. Cell membrane coated semiconducting polymer nanoparticles for enhanced multimodal cancer phototheranostics. *ACS Nano*. 2018;12(8):8520–8530. https://doi.org/10.1021/acsnano.8b04331

39. Li, X., Yang, C., Tao, Y., Hou, X., Liu, Y., Sang, H., & Jiang, G. (2021). Near-Infrared Light-Triggered Thermosensitive Liposomes Modified with Membrane Peptides for the Local Chemo/Photothermal Therapy of Melanoma. *OncoTargets and therapy*, *14*, 1317–1329. https://doi.org/10.2147/OTT.S287272

40. Ugwueze VU, Chukwunweike JN. Continuous integration and deployment strategies for streamlined DevOps in software engineering and application delivery. Int J Comput Appl Technol Res. 2024;14(1):1–24. doi:10.7753/IJCATR1401.1001.

41. Dorgbefu EA. Leveraging predictive analytics for real estate marketing to enhance investor decision-making and housing affordability outcomes. Int J Eng Technol Res Manag. 2018;2(12):135. Available from: https://doi.org/10.5281/zenodo.15708955.

42. Chibogwu Igwe-Nmaju. AI and automation in organizational messaging: ethical challenges and human-machine interaction in corporate communication. *International Journal of Engineering Technology Research & Management*. 2021 Dec;5(12):256. Available from: doi: https://doi.org/10.5281/zenodo.15562214

43. Alawode Adedapo. Assessing climate change impacts on agricultural productivity and rural livelihoods in Sub-Saharan Africa. *Int J Res Publ Rev.* 2025 May;6(5):4508-4523. Available from: https://doi.org/10.55248/gengpi.6.0525.1734

44. Ndubuisi Amarachi F. Cybersecurity incident response and crisis management in the United States. *Int J Comput Appl Technol Res.* 2025;14(1):79-92. Available from: https://doi.org/10.7753/IJCATR1401.1006

45. Senaya GM. Financial literacy and its role in promoting sustainable investment. *World Journal of Advanced Research and Reviews*. 2024;24(01):212–232. doi: https://doi.org/10.30574/wjarr.2024.24.1.2986.

46. Dorgbefu EA. Using business analytics to tailor real estate messaging for inclusive housing solutions and investment impact. Int J Eng Technol Res Manag. 2020;4(12):156. Available from: https://doi.org/10.5281/zenodo.15708955.

47. Adedapo Alawode. Assessing climate change impacts on agricultural productivity and rural livelihoods in Sub-Saharan Africa. *International Journal of Research Publication and Reviews (2025)*. Available from: https://doi.org/10.55248/gengpi.6.0525.1734

48. Ndubuisi Amarachi F. The intersection of false projections, identity manipulation, and emerging financial cybercrime threats. *Int J Res Publ Rev.* 2024 Dec;5(12):5529-5546. Available from: https://doi.org/10.55248/gengpi.5.1224.0237

49. Adenuga, T., Ayobami, A.T., Mike-Olisa, U. & Okolo, F.C., 2024. Leveraging generative AI for autonomous decision-making in supply chain operations: A framework for intelligent exception handling. International Journal of Computer Sciences and Engineering, 12(5), pp.92–102. Available at: https://doi.org/10.32628/CSEIT24102138.

50. Chukwunweike J, Lawal OA, Arogundade JB, Alade B. Navigating ethical challenges of explainable AI in autonomous systems. *International Journal of Science and Research Archive*. 2024;13(1):1807–19. doi:10.30574/ijsra.2024.13.1.1872. Available from: https://doi.org/10.30574/ijsra.2024.13.1.1872.

51. Huang X, Zhang W, Guan G, Song G, Zou R, Hu J. Design and functionalization of the NIR-responsive photothermal semiconductor nanomaterials for cancer theranostics. Accounts of chemical research. 2017 Oct 17;50(10):2529-38.

52. Zhao Y, Chen BQ, Kankala RK, Wang SB, Chen AZ. Recent advances in combination of copper chalcogenide-based photothermal and reactive oxygen species-related therapies. ACS Biomaterials Science & Engineering. 2020 Aug 11;6(9):4799-815.

53. Senaya G. Mitigating financial risks for entrepreneurs in emerging markets through financial literacy. *World Journal of Advanced Research and Reviews*. 2025 Jan;25(1):602–620. doi: https://doi.org/10.30574/wjarr.2025.25.1.0059.

54. Qin Z, Qiu M, Zhang Q, Yang S, Liao G, Xiong Z, Xu Z. Development of copper vacancy defects in a silver-doped CuS nanoplatform for high-efficiency photothermal–chemodynamic synergistic antitumor therapy. Journal of Materials Chemistry B. 2021;9(42):8882-96.

55. Adedapo Alawode, and Obunadike ThankGod Chiamaka. EVALUATING FINANCIAL DERIVATIVES IN AGRICULTURAL RISK MANAGEMENT: IMPLICATIONS FOR MARKET STABILITY AND PRICE TRANSMISSION. International Journal Of Engineering Technology Research & Management (IJETRM). 2023Dec21;07(12):410–26.

56. Yu S, Xia G, Yang N, Yuan L, Li J, Wang Q, Li D, Ding L, Fan Z, Li J. Noble metal nanoparticle-based photothermal therapy: development and application in effective cancer therapy. International Journal of Molecular Sciences. 2024 May 22;25(11):5632.

57. Adeoluwa Abraham Olasehinde, Anthony Osi Blessing, Somadina Obiora Chukwuemeka. DEVELOPMENT OF BIO-PHOTONIC FEEDBACK SYSTEMS FOR REAL-TIME PHENOTYPIC RESPONSE MONITORING IN INDOOR CROPS. International Journal of Engineering Technology Research & Management (IJETRM). 2024Dec21;08(12):486–506.

58. Li B, Wang Q, Zou R, Liu X, Xu K, Li W, Hu J. Cu 7.2 S 4 nanocrystals: a novel photothermal agent with a 56.7% photothermal conversion efficiency for photothermal therapy of cancer cells. Nanoscale. 2014;6(6):3274-82.

59. Peng S, He Y, Er M, Sheng Y, Gu Y, Chen H. Biocompatible CuS-based nanoplatforms for efficient photothermal therapy and chemotherapy in vivo. Biomaterials Science. 2017;5(3):475-84.

60. Wei W, Zhang X, Zhang S, Wei G, Su Z. Biomedical and bioactive engineered nanomaterials for targeted tumor photothermal therapy: A review. Materials Science and Engineering: C. 2019 Nov 1;104:109891.